Indoleamine 2,3-dioxygenase (IDO) inhibitors
US7799776B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 13, 2005 |
| Grant date | Sep 21, 2010 |
| Priority date | — |
| Expiry date | Feb 12, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2603/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell mediated immune response or may directly result from depletion of tryptophan or accumulation of a product of tryptophan degradation. Specific disease conditions include cataracts, age-related yellowing in the eye, neurodegenerative disorders, mood disorders, cancer and various bacterial/viral infections. IDO inhibitors of this invention are substituted naphthalene and anthracene diones. Novel compounds of this invention include the following taurine-substituted naphthaquinone structure.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.